Biosimilars in Oncology

Bioequivalence assessment is a crucial step in the evaluation of generic drugs or biosimilar products. It compares the pharmacokinetic and sometimes pharmacodynamic properties of a generic/biosimilar drug to that of a reference drug (innovator drug) to determine if they are equivalent in terms of safety and efficacy.

The purpose of bioequivalence assessment is to demonstrate that the generic or biosimilar product is highly similar to the reference product, showing comparable bioavailability and similar therapeutic effects. It is based on the principle that if two products are bioequivalent, they can be expected to have the same therapeutic outcome when administered to patients at the same dosage

 

    Related Conference of Biosimilars in Oncology

    July 14-15, 2025

    15th World Glycobiology Congress

    Berlin, Germany
    July 17-18, 2025

    16th International Conference on Biofuels and Bioenergy

    Amsterdam, Netherlands
    September 08-09, 2025

    23rd International Conference on Structural Biology

    Frankfurt, Germany

    Biosimilars in Oncology Conference Speakers